<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04974853</url>
  </required_header>
  <id_info>
    <org_study_id>NMP/Aaro/21-11</org_study_id>
    <nct_id>NCT04974853</nct_id>
  </id_info>
  <brief_title>Cholesterol Lowering Effect of Cardio-Complement, an Ayurveda Formulation</brief_title>
  <official_title>Cholesterol Lowering Effect of Cardio-Complement, an Ayurveda Formulation: Feasibility Study on Patients With Mild-to-moderate Hypercholesterolemia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>NMP Medical Research Institute</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Aarogyam UK</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>NMP Medical Research Institute</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of this feasibility study was to assess the lipid-lowering effects and safety of a&#xD;
      Ayurveda formulation containing Terminalia Arjuna, Withania Sominifera, Garcinia Cambogia and&#xD;
      piperine (as bioenhancer)&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The COVID-19 related lockdowns severely affected the healthcare in India, specially in second&#xD;
      wave of COVID-19. This research presents the applicability of Ayurveda formulation to analyze&#xD;
      the impact on lipid profile during the lockdown.&#xD;
&#xD;
      Patients with hyperlipidemia who referred to Gyansanjeevani were recruited. All participants&#xD;
      were enrolled in the study after a complete physical examination and medical history remotely&#xD;
      over the virtual secure platform.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">June 1, 2021</start_date>
  <completion_date type="Actual">July 5, 2021</completion_date>
  <primary_completion_date type="Actual">June 30, 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Supportive Care</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Reduction of LDL-cholesterol</measure>
    <time_frame>Change from baseline to 2 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Reduction of total cholesterol</measure>
    <time_frame>Changes from baseline to 2 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Increase of HDL cholesterol</measure>
    <time_frame>Change from baseline to 2 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Reduction of Triglycerides</measure>
    <time_frame>Change from baseline to 2 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">22</enrollment>
  <condition>Hypercholesterolemia</condition>
  <arm_group>
    <arm_group_label>Ayurveda Formulation</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients with hypercholesterolemia treated with Ayurveda formulation, Cardio-Complement</description>
  </arm_group>
  <intervention>
    <intervention_type>Combination Product</intervention_type>
    <intervention_name>Cardio-complement</intervention_name>
    <description>Ayurvedic combination of Terminalia Arjuna, Withania Sominifera, Garcinia Cambogia and piperine (as bioenhancer) in pre-specified dosage.</description>
    <arm_group_label>Ayurveda Formulation</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Age between 18 and 65 years&#xD;
&#xD;
          -  BMI between 18.5 and 40 kg/m2&#xD;
&#xD;
          -  Total Cholesterol &gt;180 mg/dl&#xD;
&#xD;
          -  No clinically significant medical history&#xD;
&#xD;
          -  Willing to participate to the study by complying with the protocol&#xD;
&#xD;
          -  Able to provide written informed consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Metabolic disorder such as diabetes, uncontrolled thyroidal trouble or other metabolic&#xD;
             disorder,&#xD;
&#xD;
          -  Severe chronic disease&#xD;
&#xD;
          -  History of ischemic cardiovascular event,&#xD;
&#xD;
          -  Uncontrolled hypertension&#xD;
&#xD;
          -  Under treatment or dietary supplement which could affect study parameter&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Prashanna T Chockalingam</last_name>
    <role>Principal Investigator</role>
    <affiliation>NMP Medical Research Institute, India</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Abhijit Venu</last_name>
    <role>Study Chair</role>
    <affiliation>Aarogyam UK</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Skanthesh Lakshmanan</last_name>
    <role>Study Director</role>
    <affiliation>NMP Medical Research Institute, India</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Gyansanjeevani</name>
      <address>
        <city>Jaipur</city>
        <state>Rajasthan</state>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>India</country>
  </location_countries>
  <verification_date>June 2021</verification_date>
  <study_first_submitted>July 16, 2021</study_first_submitted>
  <study_first_submitted_qc>July 16, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">July 23, 2021</study_first_posted>
  <last_update_submitted>July 16, 2021</last_update_submitted>
  <last_update_submitted_qc>July 16, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">July 23, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Ayurveda</keyword>
  <keyword>Cholesterol</keyword>
  <keyword>Cardiovascular Diseases</keyword>
  <keyword>Hyperlipidemia</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypercholesterolemia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Complement System Proteins</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

